paclitaxel protein bound + gemcitabine + cisplatin + paricalcitol

The combination of paclitaxel protein bound (nab-paclitaxel), gemcitabine, cisplatin, and paricalcitol is a neoadjuvant chemotherapy regimen being evaluated by the HonorHealth Research Institute for the treatment of pancreatic adenocarcinoma. This four-drug regimen, sometimes referred to as G-PaC plus paricalcitol, is specifically studied in patients with untreated resectable, borderline resectable, or locally advanced pancreatic ductal adenocarcinoma. The regimen's primary goal is to achieve CA 19-9 normalization prior to surgical resection. Nab-paclitaxel acts as a microtubule stabilizer to inhibit cell division, while gemcitabine and cisplatin serve as cytotoxic agents that interfere with DNA synthesis and repair. Paricalcitol, a vitamin D receptor (VDR) agonist, is included to modulate the dense tumor stroma characteristic of pancreatic cancer, potentially enhancing the delivery and efficacy of the cytotoxic agents by remodeling the tumor microenvironment.

Other names

nab-paclitaxel + gemcitabine + cisplatin + paricalcitolAbraxane + gemcitabine + cisplatin + paricalcitolG-PaC + paricalcitol